PDS Biotechnology Corporation (PDSB)
| Market Cap | 53.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.60M |
| Shares Out | 45.71M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 800,291 |
| Open | 1.260 |
| Previous Close | 1.230 |
| Day's Range | 1.160 - 1.320 |
| 52-Week Range | 0.851 - 4.290 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+754.7%) |
| Earnings Date | Aug 13, 2025 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protei... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 754.70% from the latest price.
News
PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Frank K. Bedu-Addo - President, CEO & Director Kirk V.
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Offic...
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 ...
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting
PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biot...
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief M...
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12...
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpo...